Limit Use of Unproven Outpatient Treatments for COVID-19

We’re hearing about lots of oral “cocktails” to treat COVID-19 in outpatients...with azithromycin, dexamethasone, ivermectin, etc.

It’s tempting to try to repurpose affordable, relatively safe meds...grasping for something to help.

Currently the only authorized options for outpatients are the monoclonal antibodies bamlanivimab or casirivimab/imdevimab...given as IV infusions to those at high risk of serious COVID-19 complications.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote